​Did a Non‐Medical Biosimilar Switching Policy Cause an Increase in Non‐Biologic/Biosimilar Health Care Resource Utilization or Cost in Patients With Inflammatory Arthritis?

Ähnliche Einträge

• The Association of Rheumatologist Supply and Multidisciplinary Care With Timely Patient Access to Rheumatologists: Evidence From British Columbia, Canada
  von: Norma K. Biln, et al.
  Veröffentlicht: (2024)
• High Health Care Utilization Preceding Diagnosis With Juvenile Idiopathic Arthritis
  von: Anna Costello, et al.
  Veröffentlicht: (2026)
• Utilization of Biologic Disease‐Modifying Antirheumatic Therapy in Patients With Rheumatoid Arthritis and Recently Diagnosed Breast Cancer
  von: Juan I. Ruiz, et al.
  Veröffentlicht: (2024)
• “What Came First?” Population‐Based Evaluation of Health Care Encounters for Depression and Anxiety Before and After Inflammatory Arthritis Diagnosis: Disentangling the Relationship Between Mental Health and Arthritis
  von: Alyssa Howren, et al.
  Veröffentlicht: (2024)
• Assessment of Pain Types in Recently Diagnosed Patients With Inflammatory Arthritis
  von: Zoe Rutter‐Locher, et al.
  Veröffentlicht: (2025)